FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Cantor Fitzgerald lifted their FY2025 earnings per share estimates for shares of 4D Molecular Therapeutics in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($3.22) for the year, up from their previous forecast of ($3.46). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

FDMT has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. Leerink Partners decreased their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Bank of America cut their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Morgan Stanley reduced their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. Finally, Chardan Capital cut their price objective on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.38.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $4.14 on Thursday. The firm has a 50-day simple moving average of $5.08 and a 200-day simple moving average of $8.34. 4D Molecular Therapeutics has a one year low of $3.92 and a one year high of $36.25. The firm has a market cap of $191.69 million, a P/E ratio of -1.45 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10).

Hedge Funds Weigh In On 4D Molecular Therapeutics

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its holdings in shares of 4D Molecular Therapeutics by 1,607.1% during the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock valued at $7,913,000 after buying an additional 1,337,497 shares during the period. Braidwell LP boosted its holdings in 4D Molecular Therapeutics by 231.7% in the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after purchasing an additional 855,990 shares during the period. JPMorgan Chase & Co. grew its position in shares of 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock valued at $4,568,000 after buying an additional 504,086 shares during the last quarter. Norges Bank bought a new position in 4D Molecular Therapeutics during the 4th quarter worth $2,790,000. Finally, Cubist Systematic Strategies LLC boosted its stake in 4D Molecular Therapeutics by 2,084.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company’s stock valued at $2,500,000 after purchasing an additional 428,285 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.